Advertisement


Primo Lara, MD, on RCC: Expert Perspective on Three Key Papers

2017 ASCO Annual Meeting

Advertisement

Primo Lara, MD, of the University of California, Davis Comprehensive Cancer Center, discusses three top abstracts on treating advanced renal cell carcinoma with epacadostat, pembrolizumab, atezolizumab, bevacizumab, sunitinib, or pazopanib. (Abstracts 4505, 4507, 4515)



Related Videos

Gynecologic Cancers

Ronald J. Buckanovich, MD, PhD, on Ovarian Cancer: Expert Perspective on the ICON6 Trial

Ronald J. Buckanovich, MD, PhD, of the University of Michigan, discusses study findings on chemotherapy and cediranib in relapsed ovarian cancer. (Abstract 5506)

Colorectal Cancer

Axel Grothey, MD, on Colon Cancer: Results of the IDEA Collaboration

Axel Grothey, MD, of the Mayo Clinic Rochester, discusses study findings on shortening the duration of adjuvant oxaliplatin-based therapy, linked to neurotoxicity, for patients with stage III colon cancer. (Abstract LBA1)

Lung Cancer

Alice Tsang Shaw, MD, PhD, and Tony Mok, MD, on NSCLC: Results From the ALEX and ARCHER 1050 Trials

Alice Tsang Shaw, MD, PhD, of Massachusetts General Hospital, and Tony Mok, MD, of the Chinese University of Hong Kong, discuss their two ASCO-featured abstracts on non–small cell lung cancer: alectinib vs crizotinib in treatment-naive advanced ALK+ disease, and dacomitinib vs gefitinib for first-line treatment of advanced EGFR+ disease. (Abstracts LBA9008 and LBA9007)

Kidney Cancer

Toni K. Choueiri, MD, and Sumanta K. Pal, MD, on Top Kidney Cancer Abstracts: Expert Perspectives

Sumanta K. Pal, MD, of City of Hope, and Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, exchange views on the key papers in renal cell carcinoma presented at ASCO’s 2017 nonprostate GU oral abstract session. (Abstracts 4504, 4505, 4506, 4507, 4508)

Lung Cancer
Cost of Care

Daniel A. Goldstein, MD, on Pembrolizumab for Lung Cancer: Saving Costs by Adjusting Dosage

Daniel A. Goldstein, MD, of Emory University and Rabin Medical Center, discusses his study findings that show nearly $1 billion in savings when patients receive personal weight-based doses instead of a predetermined fixed dose for treatment of PD-L1-positive non–small cell lung cancer. (Abstract 9013)

Advertisement

Advertisement




Advertisement